跳至主要内容
临床试验/NCT02731092
NCT02731092Unknown1 期

Safety and Tolerability of Lactoferrin in Very Low Birth Weight Infants

University of Virginia4 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2016年4月最近更新:
适应症

试验速览

阶段
1 期
入组人数
30
试验地点
4
主要终点
Definitely related study solution serious adverse event

研究概览

简要总结

To evaluate the safety and tolerability of three different lactoferrin doses in preterm infants

详细描述

Aim1: To evaluate the safety and tolerability of three different lactoferrin doses in preterm infants

  1. Lactoferrin related adverse events and serious adverse events
  2. Number of infants reaching full feeds while receiving lactoferrin (120 ml/kg/day)
  3. Episodes of not receiving enteral feedings for > 24 hours once feeding is initiated

Aim 2: To evaluate lactoferrin absorption and excretion.

  1. Examine lactoferrin levels in saliva, urine, plasma and stool
  2. Examine lactoferrin levels in maternal and human donor milk.

Aim 3: To evaluate the effect of lactoferrin on the intestinal microbiome structure.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 14 Days(Child)
性别
All
接受健康志愿者

入选标准

  • < 15 days of age and receiving enteral feedings
  • < 1500 grams birth weight
  • <37 weeks gestation

排除标准

  • Congenital bowel obstruction ( esophageal, duodenal, small bowel or anal atresias, Hirschsprung disease, malrotation)
  • Known necrotizing enterocolitis or bowel perforation

结局指标

主要结局

Definitely related study solution serious adverse event

时间窗: 30 days while receiving study solution

次要结局

  • Number of infants reaching 120 ml/kg of enteral feeds(30 days while receiving study solution)
  • Number of days not receiving any feedings after lactoferrin administration(30 days while receiving study solution)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

David A Kaufman

MD

University of Virginia

研究点 (4)

Loading locations...

相似试验